Literature DB >> 23800395

The expression and regulation of microRNA-125b in cancers.

Ke Huang1, Shiwu Dong, Wei Li, Zhao Xie.   

Abstract

Cancer is one of the leading causes of death worldwide. There is a definite need for novel approaches to improve the diagnostics and treatment of cancers. The pathological processes leading to carcinoma are associated with the altered expression of a specific gene relevant to malignancy. MicroRNA-125b (miR-125b) is a small non-coding, multipurpose miRNA that plays a key role in several different biological processes. Increasing amounts of evidence indicates that miR-125b may serve as a diagnostic biomarker of certain kinds of cancers. miR-125b may be suitable to be used as a therapeutical target in several human diseases including neoplastic disease. Here, we review the latest progress in the identification and validation of the relationship between cancer-related miR-125b and cancers, and discuss the functions of miR-125b that regulates many processes of diseases, including cell proliferation, differentiation, and apoptosis.

Entities:  

Keywords:  cancer; gene expression; miR-125b; target gene

Mesh:

Substances:

Year:  2013        PMID: 23800395     DOI: 10.1093/abbs/gmt073

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  12 in total

1.  MicroRNA-125b in peripheral blood: a potential biomarker for severity and prognosis of children with viral encephalitis.

Authors:  Qin-Ling Gao; Yun-Xia Ma; Da-Wei Yuan; Qing-Cai Zhang; Jun Zeng; Hao Li
Journal:  Neurol Sci       Date:  2017-05-13       Impact factor: 3.307

2.  Prognostic marker microRNA-125b inhibits tumorigenic properties of hepatocellular carcinoma cells via suppressing tumorigenic molecule eIF5A2.

Authors:  Felice H Tsang; Victor Au; Wen-Jing Lu; Felix H Shek; Angela M Liu; John M Luk; Sheung-Tat Fan; Ronnie T P Poon; Nikki P Lee
Journal:  Dig Dis Sci       Date:  2014-05-09       Impact factor: 3.199

Review 3.  Inflammation related miRNAs as an important player between obesity and cancers.

Authors:  Morteza Gholami; Bagher Larijani; Zhila Zahedi; Fatemeh Mahmoudian; Samira Bahrami; Sima Parvizi Omran; Zahra Saadatian; Shirin Hasani-Ranjbar; Reza Taslimi; Milad Bastami; Mahsa M Amoli
Journal:  J Diabetes Metab Disord       Date:  2019-11-26

4.  Ganoderma lucidum polysaccharide extract inhibits hepatocellular carcinoma growth by downregulating regulatory T cells accumulation and function by inducing microRNA-125b.

Authors:  Aimei Li; Xuanyu Shuai; Zhijun Jia; Hangyu Li; Xiubin Liang; Dongming Su; Wanhua Guo
Journal:  J Transl Med       Date:  2015-03-26       Impact factor: 5.531

5.  Integrated miRNA profiling and bioinformatics analyses reveal potential causative miRNAs in gastric adenocarcinoma.

Authors:  Xiaojing Zhang; Yin Peng; Zhe Jin; Weiling Huang; Yulan Cheng; Yudan Liu; Xianling Feng; Mengting Yang; Yong Huang; Zhenfu Zhao; Liang Wang; Yanjie Wei; Xinmin Fan; Duo Zheng; Stephen J Meltzer
Journal:  Oncotarget       Date:  2015-10-20

6.  A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas.

Authors:  Giulia Regazzo; Irene Terrenato; Manuela Spagnuolo; Mariantonia Carosi; Gaetana Cognetti; Lucia Cicchillitti; Francesca Sperati; Veronica Villani; Carmine Carapella; Giulia Piaggio; Andrea Pelosi; Maria Giulia Rizzo
Journal:  J Exp Clin Cancer Res       Date:  2016-07-30

7.  GATA4 promotes hepatoblastoma cell proliferation by altering expression of miR125b and DKK3.

Authors:  Yihua Pei; Qin Yao; Sibo Yuan; Bozhen Xie; Yan Liu; Chunsheng Ye; Huiqin Zhuo
Journal:  Oncotarget       Date:  2016-11-22

8.  Low tissue levels of miR-125b predict malignancy in solitary fibrous tumors of the pleura.

Authors:  Matthias Brock; Selma Hottinger; Matthias Diebold; Alex Soltermann; Wolfram Jochum; Malcolm Kohler; Lars C Huber; Daniel P Franzen
Journal:  Respir Res       Date:  2017-03-02

9.  Ferritin heavy chain is a negative regulator of ovarian cancer stem cell expansion and epithelial to mesenchymal transition.

Authors:  Nadia Lobello; Flavia Biamonte; Maria Elena Pisanu; Maria Concetta Faniello; Žiga Jakopin; Emanuela Chiarella; Emilia Dora Giovannone; Rita Mancini; Gennaro Ciliberto; Giovanni Cuda; Francesco Costanzo
Journal:  Oncotarget       Date:  2016-09-20

10.  Doxorubicin-induced loss of DNA topoisomerase II and DNMT1- dependent suppression of MiR-125b induces chemoresistance in ALK-positive cells.

Authors:  Annabelle Congras; Nina Caillet; Nouritza Torossian; Cathy Quelen; Camille Daugrois; Pierre Brousset; Laurence Lamant; Fabienne Meggetto; Coralie Hoareau-Aveilla
Journal:  Oncotarget       Date:  2018-02-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.